When was Eledon founded?

Eledon was founded in 2004 and raised its 1st funding round 7 years after it was founded.

Where is Eledon located?

Eledon is headquartered in Irvine, United States.

How many employees does Eledon have?

As of May 31, 2026, the latest employee count at Eledon is 41.

Is Eledon a funded company?

Eledon is a funded company, having raised a total of $1.89M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 13, 2011.

When was the latest funding round of Eledon?

Eledon's latest funding was a $***** Post IPO round on May 09, 2024, with participation from 0 investor.

Where does Eledon rank among its competitors?

Eledon ranks 325th amongst 3189 active competitors, of which 1105 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Eledon, which secured $50M in May, 2024.

Who are the top competitors of Eledon?

Eledon's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Eledon secured the most recent funding round in May, 2024.

Eledon - 2026 Company Profile, Funding, Competitors & Financials

Eledon is a public company based in Irvine (United States), founded in 2004. It operates as a Provider of therapeutics solution for organ or cellular transplantation in autoimmune and neurodegenerative disease. Eledon has raised $1.89M in funding. The company has 3189 active competitors, including 1105 funded and 797 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.

Company Details

Provider of therapeutics solution for organ or cellular transplantation in autoimmune and neurodegenerative disease. The company targets the CD40L pathway and anti-CD40 Ligand (CD40L) pathway antibodies. The company lead product is AT-1501, for pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation. The other lead product is AT-2001 to target autoimmune indications.

Website: eledon.com
Social
Email ID: *****@eledon.com
Phone Number: +1 **********

Key Metrics

Founded Year

2004

Location

Irvine, United States

Stage

Public

Total Funding

$1.89M in 7 rounds

Latest Funding Round

Post IPO, May 09, 2024, $*****

Investors

BVF Partners & 5 more

Ranked

325^th among 3189 active competitors

Employee Count

41 as on May 31, 2026

Investment & Acquisitions

Anelixis Therapeutics

Similar Companies

Jazz Pharmaceuticals & 1097 more

Exit Details

Public

View Eledon's full profile

Eledon is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ELEDON PHARMACEUTICALS, INC. CIN: 3782904 , United States, Active	Mar 25, 2004	-	17 (As on Dec 31, 2022)	-
NOVUS THERAPEUTICS, INC. CIN: 1404281 , United States, Active		-	-	-

Eledon got listed on Sep 22, 2014.

Click here to take a look at Eledon's IPO in detail

Eledon has raised a total funding of $1.89M over 7 rounds. Its first funding round was on Sep 13, 2011. Eledon has 6 institutional investors.

Here is the list of recent funding rounds of Eledon:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 09, 2024	6521010	Post IPO	3354239	4154574	3130347	2824124
May 19, 2023	2934281	Post IPO	2744976	4816304	4635561	5528383
Sep 14, 2020	5171093	Post IPO	6647318	5259327	2839893	BVF Partners

Access funding benchmarks and valuations. Sign up today!

View details of Eledon's funding rounds and investors

Eledon's employee count trend

Eledon has 41 employees as of May 26. Here is Eledon's employee count trend over the years:

Uncover Eledon's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Eledon include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Eledon, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 10 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 27 others	77/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
6th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
7th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
8th	CareDx 1998, Brisbane (United States), Public	Developer of medical solutions for transplant patients	$138M	Integral Capital Partners, Intel & 24 others	73/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
10th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
325th	Eledon 2004, Irvine (United States), Public	Provider of therapeutics solution for organ or cellular transplantation in autoimmune and neurodegenerative disease	$1.89M	BVF Partners, Orbimed & 4 others	57/100